NCT01732757

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 157 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	Alcaftadine 0.25%	One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
DRUG	Olopatadine 0.2%	One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
DRUG	dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%	One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Timeline

• Start date: 2012-11-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2012-11-26
• Last updated: 2014-01-14
• Results posted: 2014-01-14

Locations

1 site across 1 country: United States